Pacer Advisors, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Pacer Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$37.42 - $51.61 $4,565 - $6,296	-122 Reduced 14.52%	718 $29,000
Q1 2024 May 10, 2024	BUY	$43.02 - $53.69 $36,136 - $45,099	840 New	840 $39,000
Q2 2021 Jul 21, 2021	SELL	$92.19 - $115.71 $56,143 - $70,467	-609 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$106.9 - $167.73 $31,642 - $49,648	-296 Reduced 32.71%	609 $69,000
Q4 2020 Jan 20, 2021	SELL	$84.4 - $177.39 $53,847 - $113,174	-638 Reduced 41.35%	905 $125,000
Q3 2020 Oct 19, 2020	BUY	$72.98 - $90.0 $112,608 - $138,870	1,543 New	1,543 $127,000
Q4 2018 Feb 13, 2019	SELL	$38.89 - $77.3 $113,169 - $224,943	-2,910 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $208,967 - $262,336	2,910 New	2,910 $222,000
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $48,763 - $64,372	-1,100 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $47,894 - $63,052	1,100	1,100 $51,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.